Journal of Molecular and Cellular Cardiology
Volume 42, Issue 2 , Pages 333-342 , February 2007

AMPK control of myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes

  • Girish Kewalramani

      Affiliations

    • Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3
    • These two authors contributed equally to the work reported here.
    • ,
  • Ding An

      Affiliations

    • Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3
    • These two authors contributed equally to the work reported here.
    • ,
  • Min Suk Kim

      Affiliations

    • Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3
    • ,
  • Sanjoy Ghosh

      Affiliations

    • Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3
    • ,
  • Dake Qi

      Affiliations

    • Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3
    • ,
  • Ashraf Abrahani

      Affiliations

    • Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3
    • ,
  • Thomas Pulinilkunnil

      Affiliations

    • Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3
    • ,
  • Vijay Sharma

      Affiliations

    • Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3
    • ,
  • Richard B. Wambolt

      Affiliations

    • Department of Pathology and Laboratory Medicine, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3
    • ,
  • Michael F. Allard

      Affiliations

    • Department of Pathology and Laboratory Medicine, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3
    • ,
  • Sheila M. Innis

      Affiliations

    • Department of Pediatrics, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3
    • ,
  • Brian Rodrigues

      Affiliations

    • Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3
    • Corresponding Author InformationCorresponding author. Tel.: +1 604 822 4758; fax: +1 604 822 3035.

Received 13 September 2006 ,Revised 18 October 2006 ,Accepted 13 November 2006.

References 

  1. Rodrigues B, McNeill JH. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc. Res. 1992;26:913–922
  2. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–789
  3. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 2002;109:121–130
  4. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J. Biol. Chem. 1997;272:28210–28217
  5. Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 1998;273:23786–23792
  6. Varanasi U, Chu R, Huang Q, Castellon R, Yeldandi AV, Reddy JK. Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J. Biol. Chem. 1996;271:2147–2155
  7. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 2003;144:5179–5183
  8. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, et al. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr. Biol. 2002;12:1419–1423
  9. Hayashi T, Hirshman MF, Fujii N, Habinowski SA, Witters LA, Goodyear LJ. Metabolic stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling mechanism. Diabetes. 2000;49:527–531
  10. Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr. Biol. 2000;10:1247–1255
  11. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J. Biol. Chem. 1995;270:17513–17520
  12. Kudo N, Gillespie JG, Kung L, Witters LA, Schulz R, Clanachan AS, et al. Characterization of 5′AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim. Biophys. Acta. 1996;1301:67–75
  13. Luiken JJ, Coort SL, Willems J, Coumans WA, Bonen A, van der Vusse GJ, et al. Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes. 2003;52:1627–1634
  14. An D, Pulinilkunnil T, Qi D, Ghosh S, Abrahani A, Rodrigues B. The metabolic “switch” AMPK regulates cardiac heparin-releasable lipoprotein lipase. Am. J. Physiol. Endocrinol. Metab. 2005;288:246–253
  15. Kudo N, Gillespie JG, Kung L, Witters LA, Schulz R, Clanachan AS, et al. Characterization of 5′AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim. Biophys. Acta. 1996;1301:67–75
  16. Soltys CL, Kovacic S, Dyck JR. Activation of cardiac AMP-activated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. Am. J. Physiol. Heart Circ. Physiol. 2006;290:H2472–H2479
  17. Coven DL, Hu X, Cong L, Bergeron R, Shulman GI, Hardie DG, et al. Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise. Am. J. Physiol. Endocrinol. Metab. 2003;285:E629–E636
  18. Sambandam N, Abrahani MA, St Pierre E, Al-Atar O, Cam MC, Rodrigues B. Localization of lipoprotein lipase in the diabetic heart: regulation by acute changes in insulin. Arterioscler. Thromb. Vasc. Biol. 1999;19:1526–1534
  19. Ghosh S, Qi D, An D, Pulinilkunnil T, Abrahani A, Kuo KH, et al. Brief episode of STZ-induced hyperglycemia produces cardiac abnormalities in rats fed a diet rich in n-6 PUFA. Am. J. Physiol. Heart Circ. Physiol. 2004;287:H2518–H2527
  20. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 2005;85:1093–1129
  21. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ. Res. 2004;95:568–578
  22. Taylor EB, Ellingson WJ, Lamb JD, Chesser DG, Winder WW. Long-chain acyl-CoA esters inhibit phosphorylation of AMP-activated protein kinase at threonine-172 by LKB1/STRAD/MO25. Am. J. Physiol. Endocrinol. Metab. 2005;288:E1055–E1061
  23. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15–25
  24. Beauloye C, Marsin AS, Bertrand L, Krause U, Hardie DG, Vanoverschelde JL, et al. Insulin antagonizes AMP-activated protein kinase activation by ischemia or anoxia in rat hearts, without affecting total adenine nucleotides. FEBS Lett. 2001;505:348–352
  25. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J. Biol. Chem. 2003;278:39422–39427
  26. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. U. S. A. 1997;94:4318–4323
  27. Depre C, Young ME, Ying J, Ahuja HS, Han Q, Garza N, et al. Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J. Mol. Cell Cardiol. 2000;32:985–996
  28. Saddik M, Gamble J, Witters LA, Lopaschuk GD. Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. J. Biol. Chem. 1993;268:25836–25845
  29. Pulinilkunnil T, Abrahani A, Varghese J, Chan N, Tang I, Ghosh S, et al. Evidence for rapid “metabolic switching” through lipoprotein lipase occupation of endothelial-binding sites. J. Mol. Cell Cardiol. 2003;35:1093–1103
  30. Sakamoto J, Barr RL, Kavanagh KM, Lopaschuk GD. Contribution of malonyl-CoA decarboxylase to the high fatty acid oxidation rates seen in the diabetic heart. Am. J. Physiol. Heart Circ. Physiol. 2000;278:196–204
  31. Wang MY, Unger RH. Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone. Am. J. Physiol. Endocrinol. Metab. 2005;288:E216–E221
  32. Atkinson LL, Kozak R, Kelly SE, Onay Besikci A, Russell JC, Lopaschuk GD. Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. Am. J. Physiol. Endocrinol. Metab. 2003;284:E923–E930
  33. Folmes CD, Clanachan AS, Lopaschuk GD. Fatty acids attenuate insulin regulation of 5′-AMP-activated protein kinase and insulin cardioprotection after ischemia. Circ. Res. 2006;99:61–68
  34. Clark H, Carling D, Saggerson D. Covalent activation of heart AMP-activated protein kinase in response to physiological concentrations of long-chain fatty acids. Eur. J. Biochem. 2004;271:2215–2224
  35. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 2002;109:121–130
  36. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J. Am. Coll. Cardiol. 1989;14:49–57
  37. Russell RR, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Invest. 2004;114:495–503
  38. Xing Y, Musi N, Fujii N, Zou L, Luptak I, Hirshman MF, et al. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J. Biol. Chem. 2003;278:28372–28377
  39. Di Filippo C, Marfella R, Cuzzocrea S, Piegari E, Petronella PI, Giugliano D, et al. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes. 2005;54:803–810

PII: S0022-2828(06)01029-7

doi: 10.1016/j.yjmcc.2006.11.010

Journal of Molecular and Cellular Cardiology
Volume 42, Issue 2 , Pages 333-342 , February 2007

Article Tools

* Image Usage & Resolution